Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da Universidade Federal do Ceará (UFC) |
Texto Completo: | http://www.repositorio.ufc.br/handle/riufc/2737 |
Resumo: | A randomized, double-blind, placebo-controlled study of the use of botulinum toxin type A in the prophylactic treatment of Migraine is presented. Migraine is a common type of primary, benign, episodic headache. It is characterized by pain usually unilateral and throbbing. Other associated symptoms are nausea, sensitivity to light and sound, or irritability. The pain is usually worsened by physical activity. There are also motor, sensitive, or visual neurological alterations, denominated aura. The physiopathology of migraine is not still perfectly understood but it could involve liberation of vasoactive neuropeptides as Substance P, Neurokinine A, and Calcitonin gene-related peptide, promoting an inflammation. Migraine, then, would be the result of a complex process that would involve the brainstem and induce local inflammation of cranial blood vessels. In spite of the therapeutic options (analgesics, steroidal and non-steroidal anti-inflammatory, triptans, neuroleptics, ergot derivatives, and opioids) only about one third of patients is satisfied with the treatment. The preventive treatment is appropriate for those that have frequent crises. It was observed that the patients using botulinum toxin for aesthetic treatment of wrinkles of the face, or dystonia presented a reduction in the amount of migraine crises. The botulinum toxin is a potent neurotoxin produced by the bacterium Clostridium botulinum. The action of the toxin is to inhibit the acetylcholin liberation from the nerve terminal. It acts also inhibiting the liberation of vasoactive neuropeptides. Therefore, Botulinum Toxin would act exactly in the core of the physiopathologic process of the disease. With the objective of testing possible analgesic effects of botulinum toxin in migraine without aura bearers, we performed a double-blind, controlled, and randomized study. The pain level was measured by scales and by the amount, and number of days of pain in a week, before and after botulinum toxin’s injection in muscles of the face. The placebo group received saline injection. The patients were followed for three months. At the end it was concluded that there was not statistic difference in intensity nor in frequency of the headache of the patients that used botulinum toxin in relation to the people that used placebo (saline). |
id |
UFC-7_2f7906df89f5a36db18e892b27f1be54 |
---|---|
oai_identifier_str |
oai:repositorio.ufc.br:riufc/2737 |
network_acronym_str |
UFC-7 |
network_name_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository_id_str |
|
spelling |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem auraStudy of the Action of Botulinum Toxin Type A in the Prophylaxis of Migraine Without AuraEnxaqueca sem AuraTranstornos da CefaléiaDorA randomized, double-blind, placebo-controlled study of the use of botulinum toxin type A in the prophylactic treatment of Migraine is presented. Migraine is a common type of primary, benign, episodic headache. It is characterized by pain usually unilateral and throbbing. Other associated symptoms are nausea, sensitivity to light and sound, or irritability. The pain is usually worsened by physical activity. There are also motor, sensitive, or visual neurological alterations, denominated aura. The physiopathology of migraine is not still perfectly understood but it could involve liberation of vasoactive neuropeptides as Substance P, Neurokinine A, and Calcitonin gene-related peptide, promoting an inflammation. Migraine, then, would be the result of a complex process that would involve the brainstem and induce local inflammation of cranial blood vessels. In spite of the therapeutic options (analgesics, steroidal and non-steroidal anti-inflammatory, triptans, neuroleptics, ergot derivatives, and opioids) only about one third of patients is satisfied with the treatment. The preventive treatment is appropriate for those that have frequent crises. It was observed that the patients using botulinum toxin for aesthetic treatment of wrinkles of the face, or dystonia presented a reduction in the amount of migraine crises. The botulinum toxin is a potent neurotoxin produced by the bacterium Clostridium botulinum. The action of the toxin is to inhibit the acetylcholin liberation from the nerve terminal. It acts also inhibiting the liberation of vasoactive neuropeptides. Therefore, Botulinum Toxin would act exactly in the core of the physiopathologic process of the disease. With the objective of testing possible analgesic effects of botulinum toxin in migraine without aura bearers, we performed a double-blind, controlled, and randomized study. The pain level was measured by scales and by the amount, and number of days of pain in a week, before and after botulinum toxin’s injection in muscles of the face. The placebo group received saline injection. The patients were followed for three months. At the end it was concluded that there was not statistic difference in intensity nor in frequency of the headache of the patients that used botulinum toxin in relation to the people that used placebo (saline).Estuda através de ensaio duplo cego, controlado, randomizado o efeito da Toxina Botulínica do tipo A na profilaxia de crises de migrânea sem aura. A migrânea é um tipo comum de cefaléia primária, benigna, episódica, e recorrente que se caracteriza por dor geralmente hemicrânica e pulsátil, e que é agravada pela atividade física. Existem outros sintomas associados como náuseas, fotofobia, fonofobia, ou irritabilidade. Na migrânea com aura podem também ocorrer alterações neurológicas motoras, sensitivas, ou visuais denominadas de aura. A migrânea, cuja fisiopatologia ainda não é perfeitamente compreendida, seria o resultado de um processo patológico complexo que envolveria o tronco cerebral e levaria à inflamação local de vasos sangüíneos cranianos através da liberação de neuropeptídeos vasoativos como Substância P (SP), Neurocinina A (NA), e Peptídio Relacionado ao Gene da Calcitonina (PRGC). Apesar das várias opções terapêuticas (analgésicos simples, antiinflamatórios hormonais e não hormonais, triptanos, antipsicóticos, derivados ergotamínicos, e opióides) para tratamento da crise ou para tratamento preventivo, somente cerca de um terço dos pacientes fica satisfeito com o tratamento. Foi observado que pacientes utilizando toxina botulínica para tratamento estético de rugas da face ou distonias apresentavam uma redução na quantidade de crises de migrânea. A toxina botulínica é uma potente neurotoxina produzida pela bactéria Clostridium botulinum. A ação da toxina é impedir a liberação de acetilcolina nos terminais nervosos. Ela também age inibindo a liberação de neuropeptídeos vasoativos. O uso da toxina botulínica nos faria agir exatamente no cerne do processo fisiopatológico da doença. Com o objetivo de testar esse possível efeito analgésico nos pacientes portadores de migrânea sem aura, realizou-se um estudo duplo-cego, controlado, e randomizado. Mediu-se o nível de dor através de escalas para quantificar a intensidade e o número de dias com dor na semana antes e após a injeção de Toxina Botulínica em músculos da face. O grupo controle recebeu SF como placebo. Os pacientes foram seguidos durante três meses. Ao final concluiu-se que não houve diferença estatística na intensidade nem na freqüência da dor de cabeça nos pacientes que usaram a toxina botulínica em relação aos que usaram placebo (SF).Costa , Carlos Maurício de CastroD’Almeida, José Artur Costa2012-06-13T16:51:21Z2012-06-13T16:51:21Z2004info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfD´ALMEIDA, J. A. C. Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura. 2004. 94 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2004.http://www.repositorio.ufc.br/handle/riufc/2737porreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2021-06-28T17:29:54Zoai:repositorio.ufc.br:riufc/2737Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:31:25.133235Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false |
dc.title.none.fl_str_mv |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura Study of the Action of Botulinum Toxin Type A in the Prophylaxis of Migraine Without Aura |
title |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
spellingShingle |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura D’Almeida, José Artur Costa Enxaqueca sem Aura Transtornos da Cefaléia Dor |
title_short |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
title_full |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
title_fullStr |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
title_full_unstemmed |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
title_sort |
Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura |
author |
D’Almeida, José Artur Costa |
author_facet |
D’Almeida, José Artur Costa |
author_role |
author |
dc.contributor.none.fl_str_mv |
Costa , Carlos Maurício de Castro |
dc.contributor.author.fl_str_mv |
D’Almeida, José Artur Costa |
dc.subject.por.fl_str_mv |
Enxaqueca sem Aura Transtornos da Cefaléia Dor |
topic |
Enxaqueca sem Aura Transtornos da Cefaléia Dor |
description |
A randomized, double-blind, placebo-controlled study of the use of botulinum toxin type A in the prophylactic treatment of Migraine is presented. Migraine is a common type of primary, benign, episodic headache. It is characterized by pain usually unilateral and throbbing. Other associated symptoms are nausea, sensitivity to light and sound, or irritability. The pain is usually worsened by physical activity. There are also motor, sensitive, or visual neurological alterations, denominated aura. The physiopathology of migraine is not still perfectly understood but it could involve liberation of vasoactive neuropeptides as Substance P, Neurokinine A, and Calcitonin gene-related peptide, promoting an inflammation. Migraine, then, would be the result of a complex process that would involve the brainstem and induce local inflammation of cranial blood vessels. In spite of the therapeutic options (analgesics, steroidal and non-steroidal anti-inflammatory, triptans, neuroleptics, ergot derivatives, and opioids) only about one third of patients is satisfied with the treatment. The preventive treatment is appropriate for those that have frequent crises. It was observed that the patients using botulinum toxin for aesthetic treatment of wrinkles of the face, or dystonia presented a reduction in the amount of migraine crises. The botulinum toxin is a potent neurotoxin produced by the bacterium Clostridium botulinum. The action of the toxin is to inhibit the acetylcholin liberation from the nerve terminal. It acts also inhibiting the liberation of vasoactive neuropeptides. Therefore, Botulinum Toxin would act exactly in the core of the physiopathologic process of the disease. With the objective of testing possible analgesic effects of botulinum toxin in migraine without aura bearers, we performed a double-blind, controlled, and randomized study. The pain level was measured by scales and by the amount, and number of days of pain in a week, before and after botulinum toxin’s injection in muscles of the face. The placebo group received saline injection. The patients were followed for three months. At the end it was concluded that there was not statistic difference in intensity nor in frequency of the headache of the patients that used botulinum toxin in relation to the people that used placebo (saline). |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004 2012-06-13T16:51:21Z 2012-06-13T16:51:21Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
D´ALMEIDA, J. A. C. Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura. 2004. 94 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2004. http://www.repositorio.ufc.br/handle/riufc/2737 |
identifier_str_mv |
D´ALMEIDA, J. A. C. Estudo da ação da toxina botulínica do tipo A na profilaxia da migrânea sem aura. 2004. 94 f. Tese (Doutorado em Farmacologia) - Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, 2004. |
url |
http://www.repositorio.ufc.br/handle/riufc/2737 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Ceará (UFC) instname:Universidade Federal do Ceará (UFC) instacron:UFC |
instname_str |
Universidade Federal do Ceará (UFC) |
instacron_str |
UFC |
institution |
UFC |
reponame_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
collection |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC) |
repository.mail.fl_str_mv |
bu@ufc.br || repositorio@ufc.br |
_version_ |
1813028839938326528 |